North America

Wed
06
Feb

4 best marijuana ETFs for conservative portfolios

Investors are clamoring for ways to get in on a popular, but risky, marijuana-investing craze. Despite the reality that pot is illegal under federal law, many states have legalized the substance and plenty of marijuana ETFs have cropped up as a result.

For recreational use, Oregon, Massachusetts, California and a few more states allow marijuana use. Yet, the majority of U.S. states have medical marijuana legislation in the pipeline. Presently, with the legal disconnect between federal and state law regarding marijuana use, investing directly in U.S. marijuana ETFs and stocks is risky and replete with scams and fraud.

Wed
06
Feb

Liht Cannabis to officially launch skin care product line in mid-February

Liht Cannabis Corporation reports the company will launch on Feb. 13 its new and re-formulated whole body hemp health line, PureCloud 9, which will be available through the company’s new website and online store.

The site “will offer Canadians the opportunity to order product,” notes a statement from Liht, which invests in the medical and recreational cannabis space and whose operations currently include cultivation, production and dispensary locations in the U.S.

Wed
06
Feb

Pot without plants is the goal of new cannabis fermentation venture

A US$255 million deal to convert sugar into cannabis-chemicals is opening the door to an era of pot without plants.

Amyris Inc. already works with genetically modified yeast that excrete designer molecules to make sweeteners and skin-care products. Now it plans to use that fermentation technology to convert sugarcane syrup into the active ingredients found in marijuana, the California-based company said in a statement Tuesday. Those ingredients can be used in consumer products ranging from beverages to skin creams and deodorant.

Tue
05
Feb

Why Canopy Growth stock skyrocketed 82% in January

What happened

Shares of Canadian marijuana grower Canopy Growth (NYSE:CGC) gained a whopping 82.3% in January, according to data from S&P Global Market Intelligence

For some context, the S&P 500 (including dividends) returned 8% last month. Most of Canopy's peers also had great starts to 2019, with shares of Aurora Canabis, Cronos, and Aphria up 42.9%, 89.4%, and 53.6%, respectively. 

Canopy Growth stock gained 13.6% last year as well. Thanks to its powerful start to 2019, shares are up 118% for the one-year period through Friday, Feb. 1, versus the S&P 500's 2.2% loss.

Tue
05
Feb

The marijuana producer Aurora Cannabis is surging after its partner received a license that helps it get better quality CBD (ACB)

Aurora Cannabis surged more than 9% to $8.10 a share Monday after announcing that its extraction-technology partner Radient Technologies has received its Standard Processing License from Health Canada. Shares are trading at their highest level since November 7.

Aurora says Radient's proprietary-extraction technology can achieve much higher throughputs than is possible with existing benchmark technologies. It also has the efficiency and ability to preserve the full spectrum of cannabinoids and terpenes found in the source material, the company said.

Tue
05
Feb

Valentine's day gift guide: The best cannabis beauty products

Cannabis topicals are a great way for canna-curious folk to experiment with the plant. They’re non-intoxicating, easy to use and are becoming steadily more available with every passing day, ushering in a new wave of cannabis users that go beyond millennials and Gen Xers. This is in part due to the CBD wave that rocked 2018, a trend so powerful it culminated in the passing of the Farm Bill that legalized hemp across America in December of last year.

Tue
05
Feb

Namaste Technologies plunges 21% after it fires CEO and launches strategic review

Namaste Technologies Inc., a Canadian e-commerce cannabis company worth more than $400 million in market value, has fired its CEO Sean Dollinger following an internal investigation that was spawned by a short seller report alleging Dollinger had committed securities fraud.

The company’s stock plunged 21 per cent to $1.10 at one stage on the TSX Venture Exchange Monday following the news of Dollinger’s termination.

The former CEO was fired for “breaches of fiduciary duty” and “evidence of self-dealing” surrounding the sale and subsequent transactions of Namaste’s U.S. subsidiary Dolliger Enterprises U.S. Inc., where Dollinger and Namaste’s head of marketing David Hughes had a “beneficial interest” in.

Tue
05
Feb

A foolish take: The winning strategy for marijuana investing so far in 2019

The marijuana industry has been a hotbed of investment activity, and there have been plenty of ups and downs in the share prices of cannabis stocks over the past several years. Given how new the industry is and how much competition there is among up-and-coming players in the space, it can be daunting to decide how to invest in a way that's both prudent yet also gives you a chance at strong returns.

Tue
05
Feb

These 15 marijuana stocks gained at least 50% in January

Did someone say something about a correction in marijuana stocks? Although the fourth quarter of 2018 was a bit rough on cannabis investors, January likely turned that frown upside down, and instilled a high that pot stock shareholders have come to appreciate.

For the month of January, the Horizons Marijuana Life Sciences ETF, a basket of around four dozen cannabis and cannabis-related securities with varied weightings, gained 48.3%. I'll repeat that for you skimmers: The most widely followed and first publicly traded marijuana ETF gained almost 50% in just one month.

Tue
05
Feb

Yes, medical cannabis works. So why deny the anecdotal evidence?

One of the most common arguments against the efficacy of medical cannabis today is that public policy is outpacing real science. Currently, 33 states along with the District of Columbia, Guam and Puerto Rico have passed laws for comprehensive medical cannabis programs -- but critics often point out we’re lacking definitive proof that marijuana safely and effectively treats many of the qualifying conditions.

Pages

Subscribe to RSS - North America